WallStSmart

Eton Pharmaceuticals Inc (ETON)vsTeva Pharma Industries Ltd ADR (TEVA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Teva Pharma Industries Ltd ADR generates 19817% more annual revenue ($17.32B vs $86.93M). TEVA leads profitability with a 4.1% profit margin vs -1.7%. TEVA earns a higher WallStSmart Score of 49/100 (D+).

ETON

Avoid

29

out of 100

Grade: F

Growth: 7.3Profit: 4.0Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -0.31

TEVA

Hold

49

out of 100

Grade: D+

Growth: 5.3Profit: 5.5Value: 5.0Quality: 4.0
Piotroski: 6/9Altman Z: 0.28

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ETON1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
40.4%10/10

Revenue surging 40.4% year-over-year

TEVA2 strengths · Avg: 9.0/10
EPS GrowthGrowth
72.2%10/10

Earnings expanding 72.2% YoY

PEG RatioValuation
0.968/10

Growing faster than its price suggests

Areas to Watch

ETON4 concerns · Avg: 2.3/10
Market CapQuality
$1.17B3/10

Smaller company, higher risk/reward

Price/BookValuation
41.0x2/10

Trading at 41.0x book value

Return on EquityProfitability
-4.8%2/10

ROE of -4.8% — below average capital efficiency

EPS GrowthGrowth
-12.6%2/10

Earnings declined 12.6%

TEVA4 concerns · Avg: 2.5/10
Profit MarginProfitability
4.1%3/10

4.1% margin — thin

Operating MarginProfitability
4.0%3/10

Operating margin of 4.0%

P/E RatioValuation
58.4x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-0.8%2/10

Revenue declined 0.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ETON

The strongest argument for ETON centers on Revenue Growth. Revenue growth of 40.4% demonstrates continued momentum.

Bull Case : TEVA

The strongest argument for TEVA centers on EPS Growth, PEG Ratio. PEG of 0.96 suggests the stock is reasonably priced for its growth.

Bear Case : ETON

The primary concerns for ETON are Market Cap, Price/Book, Return on Equity.

Bear Case : TEVA

The primary concerns for TEVA are Profit Margin, Operating Margin, P/E Ratio. A P/E of 58.4x leaves little room for execution misses. Debt-to-equity of 2.05 is elevated, increasing financial risk.

Key Dynamics to Monitor

ETON profiles as a hypergrowth stock while TEVA is a value play — different risk/reward profiles.

ETON carries more volatility with a beta of 0.86 — expect wider price swings.

ETON is growing revenue faster at 40.4% — sustainability is the question.

ETON generates stronger free cash flow (7M), providing more financial flexibility.

Bottom Line

TEVA scores higher overall (49/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Eton Pharmaceuticals Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and marketing pharmaceuticals for rare diseases. The company is headquartered in Deer Park, Illinois.

Teva Pharma Industries Ltd ADR

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic drugs, specialty drugs, and biopharmaceuticals in North America, Europe, and internationally. The company is headquartered in Petach Tikva, Israel.

Want to dig deeper into these stocks?